Wijnhoven S W, Kool H J, van Oostrom C T, Beems R B, Mullenders L H, van Zeeland A A, van der Horst G T, Vrieling H, van Steeg H
Department of Radiation Genetics and Chemical Mutagetesis-MGC, Leiden University Medical Center, The Netherlands.
Cancer Res. 2000 Oct 15;60(20):5681-7.
Cockayne syndrome (CS) patients are deficient in the transcription coupled repair (TCR) subpathway of nucleotide excision repair (NER) but in contrast to xeroderma pigmentosum patients, who have a defect in the global genome repair subpathway of NER, CS patients do not have an elevated cancer incidence. To determine to what extent a TCR deficiency affects carcinogen-induced mutagenesis and carcinogenesis, CS group B correcting gene (CSB)-deficient mice were treated with the genotoxic carcinogen benzo(a)pyrene (B[a]P) at an oral dose of 13 mg/kg body weight, three times a week. At different time points, mutant frequencies at the inactive lacZ gene (in spleen, liver, and lung) as well as at the active hypoxanthine phosphoribosyltransferase (Hprt) gene (in spleen) were determined to compare mutagenesis at inactive versus active genes. B[a]P treatment gave rise to increased mutant frequencies at lacZ in all of the organs tested without a significant difference between CSB-/- and wild-type mice, whereas B[a]P-induced Hprt mutant frequencies in splenic T-lymphocytes were significantly more enhanced in CSB-/- mice than in control mice. The sequence data obtained from Hprt mutants indicate that B[a]P adducts at guanine residues were preferentially removed from the transcribed strand of the Hprt gene in control mice but not in CSB-/- mice. On oral treatment with B[a]P, the tumor incidence increased in both wild-type and CSB-deficient animals. However, no differences in tumor rate were observed between TCR-deficient CSB-/- mice and wild-type mice, which is in line with the normal cancer susceptibility of CS patients. The mutagenic response at lacZ, in contrast to Hprt, correlated well with the cancer incidence in CSB-/- mice after B[a]P treatment, which suggests that mutations in the bulk of the DNA (inactive genes) are a better predictive marker for carcinogen-induced tumorigenesis than mutations in genes that are actively transcribed. Thus, the global genome repair pathway of NER appears to play an important role in the prevention of cancer.
科凯恩综合征(CS)患者在核苷酸切除修复(NER)的转录偶联修复(TCR)亚途径中存在缺陷,但与在NER的全基因组修复亚途径中有缺陷的着色性干皮病患者不同,CS患者的癌症发病率并未升高。为了确定TCR缺陷在多大程度上影响致癌物诱导的诱变和致癌作用,给CS B组校正基因(CSB)缺陷的小鼠口服剂量为13 mg/kg体重的遗传毒性致癌物苯并(a)芘(B[a]P),每周三次。在不同时间点,测定无活性的lacZ基因(在脾脏、肝脏和肺中)以及活性次黄嘌呤磷酸核糖转移酶(Hprt)基因(在脾脏中)的突变频率,以比较无活性基因与活性基因的诱变情况。B[a]P处理导致所有测试器官中lacZ的突变频率增加,CSB - / - 小鼠和野生型小鼠之间无显著差异,而B[a]P诱导的脾脏T淋巴细胞中Hprt突变频率在CSB - / - 小鼠中比对照小鼠显著增强。从Hprt突变体获得的序列数据表明,对照小鼠中鸟嘌呤残基处的B[a]P加合物优先从Hprt基因的转录链上被去除,而CSB - / - 小鼠中则不然。口服B[a]P后,野生型和CSB缺陷动物的肿瘤发病率均增加。然而,在TCR缺陷的CSB - / - 小鼠和野生型小鼠之间未观察到肿瘤发生率的差异,这与CS患者正常的癌症易感性一致。与Hprt相反,lacZ的诱变反应与B[a]P处理后CSB - / - 小鼠的癌症发病率密切相关,这表明大部分DNA(无活性基因)中的突变比活跃转录基因中的突变更能作为致癌物诱导肿瘤发生的预测标志物。因此,NER的全基因组修复途径似乎在预防癌症中起重要作用。